Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese(Queen Mary University of London), Raquel Celis(Unknown), Alessandra Nerviani(Queen Mary University of London), Bernard Lauwerys(UCB Pharma (Belgium)), Juan D. Cañete(Hospital Clínic de Barcelona), Edoardo Prediletto(Queen Mary University of London), Liliane Fossati‐Jimack, Julio Ramírez, Vasco C. Romão(Unknown), Anna E. A. Surace(Queen Mary University of London), Carlomaurizio Montecucco(University of Pavia), Giovanni Giorli(Queen Mary University of London), Pier Paolo Sainaghi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Hasan Rizvi(Queen Mary University of London), Alberto Cauli(University of Cagliari), Elisabetta Sciacca(Queen Mary University of London), Paul McKeigue(Edinburgh Cancer Research), S. Church(Nanostring Technologies (United States)), Maya H Buch(Arthritis UK), João Eurico Fonseca(University of Lisbon), Myles Lewis(Queen Mary University of London), Nagui Gendi(Basildon Hospital), Costantino Pitzalis(Queen Mary University of London), Pauline Ho(Manchester Royal Infirmary), Bhaskar DasGupta(University of Cagliari), Christopher R. John(Queen Mary University of London), Cankut Çubuk(Queen Mary University of London), Sarah Warren(Nanostring Technologies (United States)), Patrick Durez(Cliniques Universitaires Saint-Luc), Briana M. Hudson(Nanostring Technologies (United States)), Patrick Verschueren(Universitair Ziekenhuis Leuven), Manzoor Ahmed(Queen Mary University of London), Stephen Kelly(Barts Health NHS Trust), Georgina Thorborn, Michael R. Barnes(Munich Cluster for Systems Neurology), Piero Reynolds(Homerton University Hospital), Arti Mahto(King's College Hospital NHS Foundation Trust), Frances Humby(Queen Mary University of London), Nora Ng(Queen Mary University of London), Katriona Goldmann(Queen Mary University of London)
Nature Medicine
May 19, 2022
Cited by 277


Related Papers